**Acute Myeloid Leukemia (AML)** is a type of cancer affecting the blood and bone marrow. This study looks at patients with AML who have had a **stem cell transplant** (a procedure to replace damaged blood-forming cells with healthy ones) to understand why some might get sick again, called a **relapse**. The study uses **measurable residual disease (MRD) testing**, which checks for tiny amounts of cancer cells left after treatment.

This research will last about **7 years** in total, with patients participating for approximately **3 years**. During this time, up to **1,000 participants** will be asked to give **blood samples** at certain times, like every few months and if the disease returns. Past samples from diagnosis and any collected bone marrow samples will also be used for this study.

• **Study Length**: Participation is about 3 years, with sample collection at various times.
• **Eligibility**: Must be 18+, diagnosed with AML, in remission, and have not had a previous transplant.
• **Compensation/Risks**: Check with the study team for details on compensation and any risks involved.